Literature DB >> 8842048

Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein.

K Tanaka1, M Hirai, Y Tanigawara, M Yasuhara, R Hori, K Ueda, K Inui.   

Abstract

PURPOSE: P-glycoprotein-mediated transcellular transport of anticancer agents and the inhibitory effect of cyclosporin analogs and FK506 were investigated.
METHODS: The transcellular transport of daunorubicin and vinblastine by monolayers of LLC-GA5-COL150 cells which overexpressed P-glycoprotein was measured in the presence and absence of cyclosporins or FK506.
RESULTS: Cyclosporins and FK506 inhibited P-glycoprotein-mediated transport of daunorubicin and vinblastine in the order of cyclosporin D, dihydrocyclosporin D > cyclosporin A > FK506 > cyclosporin C, dihydrocyclosporin C. The intracellular accumulation of the anticancer agents was highly associated with the transporting function of P-glycoprotein. The inhibitory effect of cyclosporin D was concentration-dependent. The inhibitory effect of the modulators on P-glycoprotein was not correlated with the immunosuppressive activity, but was correlated with their lipophilicity.
CONCLUSIONS: In the transcellular transport system, lipophilicity may be one of the determinants for the inhibitory effect of various multidrug resistance modulators on the P-glycoprotein-mediated transport.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842048     DOI: 10.1023/a:1016019010339

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin.

Authors:  T Hoof; A Demmer; U Christians; B Tümmler
Journal:  Eur J Pharmacol       Date:  1993-06-15       Impact factor: 4.432

2.  FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin.

Authors:  J J Siekierka; M J Staruch; S H Hung; N H Sigal
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

3.  Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity.

Authors:  V F Quesniaux; M H Schreier; R M Wenger; P C Hiestand; M W Harding; M H Van Regenmortel
Journal:  Eur J Immunol       Date:  1987-09       Impact factor: 5.532

4.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.

Authors:  P F Augustijns; T P Bradshaw; L S Gan; R W Hendren; D R Thakker
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

Review 5.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

6.  Human P-glycoprotein transports cyclosporin A and FK506.

Authors:  T Saeki; K Ueda; Y Tanigawara; R Hori; T Komano
Journal:  J Biol Chem       Date:  1993-03-25       Impact factor: 5.157

7.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Authors:  Y Tanigawara; N Okamura; M Hirai; M Yasuhara; K Ueda; N Kioka; T Komano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

8.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes.

Authors:  P M Colombani; A Robb; A D Hess
Journal:  Science       Date:  1985-04-19       Impact factor: 47.728

10.  Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.

Authors:  M Hirai; K Tanaka; T Shimizu; Y Tanigawara; M Yasuhara; R Hori; Y Kakehi; O Yoshida; K Ueda; T Komano
Journal:  J Pharmacol Exp Ther       Date:  1995-10       Impact factor: 4.030

View more
  5 in total

1.  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

Authors:  M Katoh; M Nakajima; H Yamazaki; T Yokoi
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Authors:  Andaleeb Sajid; Natarajan Raju; Sabrina Lusvarghi; Shahrooz Vahedi; Rolf E Swenson; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

3.  Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

Authors:  Toshiyuki Sakaeda; Hideki Fujino; Chiho Komoto; Mikio Kakumoto; Jiang-Shu Jin; Koichi Iwaki; Kohshi Nishiguchi; Tsutomu Nakamura; Noboru Okamura; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.580

4.  The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.

Authors:  K Takara; Y Tanigawara; F Komada; K Nishiguchi; T Sakaeda; K Okumura
Journal:  Jpn J Cancer Res       Date:  2000-02

5.  Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.

Authors:  N Kusunoki; K Takara; Y Tanigawara; A Yamauchi; K Ueda; F Komada; Y Ku; Y Kuroda; Y Saitoh; K Okumura
Journal:  Jpn J Cancer Res       Date:  1998-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.